In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.

In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. Antimicrob Agents Chemother. 2019 Nov 11;: Authors: Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR Abstract Omadacycline is an effective therapy for community-acquired bacterial pneumonia (CABP). Given its potent activity against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA), we sought to determine the pharmacodynamic activity and target PK/PD exposures associated with therapeutic effect in the neutropenic mouse pneumonia model against 10 MSSA/MRSA strains. The area under the concentration-time curve (AUC)/MIC associated with 1-log kill was noted at 24h ELF and plasma AUC/MIC exposures of ∼2 (ELF range <0.93 to 19, plasma range <1.06 to 17) and 2-log kill noted at 24h ELF and plasma AUC/MIC exposures of ∼12 (ELF range 2.5 to 130, plasma range 3.5 to 151). PMID: 31712210 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research